BridgeBio Oncology Therapeutics annual ebitda
2023
2024
2025
BridgeBio Oncology Therapeutics EBITDA Growth & History (BBOT)
BridgeBio Oncology Therapeutics's calculated EBITDA was −$145.2M for fiscal 2025.
View full BridgeBio Oncology Therapeutics company overviewBridgeBio Oncology Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$145.2M | −$64.6M | — |
| 2024 | 2024-12-31 | −$80.7M | −$16.0M | — |
| 2023 | 2023-12-31 | −$64.7M | — | — |
BridgeBio Oncology Therapeutics quarterly ebitda
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$60.1M | −$30.1M | — |
| Q1 2026 | 2026-03-31 | −$46.1M | −$23.0M | — |
| Q4 2025 | 2025-12-31 | −$43.0M | — | — |
| Q3 2025 | 2025-09-30 | −$49.1M | — | — |
| Q2 2025 | 2025-06-30 | −$30.0M | — | — |
| Q1 2025 | 2025-03-31 | −$23.1M | — | — |
BridgeBio Oncology Therapeutics ebitda trends
Between the periods ended 2023-12-31 and 2025-12-31, BridgeBio Oncology Therapeutics's ebitda decreased from −$64.7M to −$145.2M, a change of −$80.5M. The latest reported quarter, Q2 2026, shows −$60.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Oncology Therapeutics source filings ↗